Skip to main content
Fig. 1 | BMC Urology

Fig. 1

From: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials

Fig. 1

NNT for PFS, rPFS, and freedom from PSA progression comparing enzalutamide with bicalutamide. NNT for the STRIVE (a) and TERRAIN (b) trials at 1 and 2 years. The lower limit of NNT for rPFS at 1 year was not reported, as the rate difference between enzalutamide with bicalutamide covers the 0, and it is not meaningful to report a negative NNT value. NNT number needed to treat, PFS progression-free survival, PSA prostate-specific antigen, rPFS radiographic progression-free survival

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us